Primary screening for high-risk human papillomavirus (hrHPV) requires a triage protocol.
INTRODUCTION
Because of its high sensitivity for high-grade cervical disease (i.e. cervical intraepithelial neoplasia grade 2/3, CIN2/3) and cervical cancer, testing for high-risk human papillomavirus (hrHPV) DNA is likely to become the primary method for cervical cancer screening in the near future [1] [2] [3] [4] . However, the main drawback of the hrHPV test is its lower specificity for CIN2/3 or worse (CIN2/3+) than cytology 5 . To compensate for this limitation, different triage algorithms have been suggested aiming to reduce the number of hrHPV-positive women to be referred for colposcopy, thereby limiting overdiagnosis and overtreatment. Cytology testing is nowadays considered a logical and feasible triage method. However, cytology testing at baseline alone has insufficient negative predictive value (NPV) for CIN2/3+, and thus hrHPV-positive women with a negative baseline cytology test cannot be dismissed from further follow-up. Repeat cytology testing at baseline and after 6-12 months has emerged as an effective triage approach 6, 7 , but carries the risk of loss to follow-up. Repeat cytology testing may be omitted if cytology is supplemented with another, complementary triage test at baseline. One such test, that is, HPV16/18 genotyping, seems to be useful in certain settings 6, 7 .
Measurement of DNA methylation of promoter regions of host cell tumour suppressor genes has shown promise as molecular triage test [8] [9] [10] . In our previous study, combined analysis of CADM1 (cell adhesion molecule 1) and MAL (T-lymphocyte maturation-associated protein) gene promoter methylation by quantitative methylation-specific PCR (qMSP) in hrHPVpositive cervical scrapes, revealed an equal sensitivity for CIN3+ as cytology at the same specificity 11 . Levels of CADM1 and MAL methylation in hrHPV-positive cervical scrapes increase proportionally to the degree and the duration of underlying high-grade cervical disease and are particularly high in scrapes of women with advanced CIN3 and cervical cancer 12 . Previous data 11, 13 suggest that DNA methylation analysis as triage test in hrHPVpositive women tends to be relatively more sensitive for CIN3 lesions and cervical cancer, whereas cytology is relatively more sensitive for CIN2 lesions. As such, DNA methylation analysis might be an interesting supplementary triage test to detect clinically relevant cervical lesions missed by cytology. In this study, we explored the performance of combined cytology and bi-marker CADM1/MAL methylation analysis at baseline compared with sole cytology testing at baseline, and assessed its potential as alternative triage strategy for hrHPV-positive women in cervical cancer screening.
MATERIALS AND METHODS

Cervical scrapes of hrHPV-positive women
referral algorithm as in the intervention arm of the POBASCAM trial 14 . In short, co-testing for hrHPV and cytology on the cervical scrapes at baseline was performed. Cytology was assessed according to the CISOE-A classification that can be easily converted into either the British or the 2001 Bethesda system 15 . Borderline or mild dyskaryosis (BMD) corresponds to atypical squamous cells of undetermined significance (ASCUS), atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesions (ASC-H), or low-grade squamous intraepithelial lesions (LSIL). Moderate or worse dyskaryosis (>BMD) corresponds to highgrade squamous intraepithelial lesions (HSIL). All women with >BMD cytology were directly referred for colposcopy; hrHPV-positive women with BMD cytology were advised to repeat cytology and hrHPV testing at 6 and 18 months. These women were referred for colposcopy at 6 months, if they had >BMD cytology, or BMD cytology in combination with a positive hrHPV test result. The women were referred at 18 months if they had >BMD cytology and/or an hrHPV-positive test result. Women with a positive hrHPV test result and normal cytology at baseline were advised to repeat cytology and hrHPV testing at 6 and 18 months. They were referred at 6 months if they had >BMD cytology, and were referred at 18 months if they had >BMD cytology and/or a positive hrHPV test result.
Methylation data for CADM1 and MAL genes were generated by qMSP analysis as described before 11 . In short, left-over DNA that was used for HPV testing was treated first with sodium bisulphite, and resulting converted DNA was subjected to qMSP for CADM1/MAL and ACTB as reference gene. Cq ratios were calculated (using the formula 2 [Cq(ACTB) -Cq(target)] x 100) to quantify the methylation level of the target genes. Samples with a Cq>40 were considered negative for methylation of the respective target gene, and samples with a Cq value of the 
Data and statistical analysis
Specimens were recorded as positive for methylation when either or both markers had a qMSP outcome above a predefined threshold. Thresholds have previously been set as Cq ratios giving rise to CIN3+ specificity values of >20%, >30%, >40%, >50%, >60%, >70%, and >80% 11 . Receiver operating characteristic (ROC) curves (for endpoints CIN2+ and CIN3+) were constructed for the methylation marker panel combined with cytology (i.e. recording positive if either methylation or cytology testing or both were above their threshold). The threshold used for cytology positivity was ASCUS (i.e. BMD; ref. 15) 15 . The ROC curve was compared with the CIN2+ and CIN3+ sensitivities and specificities of cytology. The positive predictive values (PPVs), NPVs and their 95% Wald confidence intervals (95% CI) were calculated for endpoints CIN2+ and CIN3+, and referral rates for colposcopy (with 95% CIs)
were determined by dividing the number of women with a positive triage test result by the number of hrHPV-positive women. For the latter analyses, the threshold that was used to score the bi-marker CADM1/MAL methylation assay positive comprised the validated Cq ratios that corresponded to a CIN3+ specificity of ≥ 70% 11 . All calculations were performed in Microsoft Excel (2010) and SPSS (version 20).
RESULTS
We determined the performance of combined triage by the bi-marker CADM1/MAL methylation assay (using validated thresholds 11 ) and cytology [threshold of ASCUS (i.e. BMD)]
in hrHPV-positive cervical scrapes for detection of CIN2+ and CIN3+, respectively. ROC curve analysis revealed that, relative to sole cytology and sole methylation testing, combined testing for both parameters yielded higher sensitivities for CIN2+ at specificities that were similar to those of sole methylation testing ( Figure 1A) . Similar findings were evident for CIN3+, although difference of ROC curves between the combined triage and methylation analysis alone was less pronounced ( Figure 1B) .
At the threshold for the bi-marker CADM1/MAL methylation assay that corresponded with ≥70% CIN3+ specificity in our previous study 11 Because increased methylation of CADM1 and MAL was found to parallel increasing severity and duration of cervical disease 12 , it is likely that additive methylation analysis particularly provides an extra safety net in terms of not missing women with advanced CIN disease or cervical cancer 10 . Studies indeed have shown that methylation assays applied to cervical scrapes or self-collected specimens detected all cervical carcinomas 11, 16, 17 . In addition, a higher detection rate of CIN3 among women of older age, which may reflect a higher duration of lesion existence, has been reported for methylation analysis 16, 17 . The preference of methylation analysis for more advanced lesions is further supported by the fact that, relative to sole cytology, the gain in sensitivity of the combined analysis is higher for CIN3+ than for CIN2+ (Table 1) . Conversely, relative to methylation testing solely, combined triage testing tends to a higher increase in sensitivity for CIN2+ and less for CIN3+ at a similar specificity ( Figure 1A and 1B) . This indicates that, in addition to overlap, both assays in part detect different lesions, with cytology having a better sensitivity for CIN2 lesions and Furthermore, it should be noted that the complementary effect of methylation marker analysis to cytology was observed in a setting where quality of cytology is high 18 . Accordingly, molecular triage by methylation markers might even be more advantageous in settings with less adequate cytology infrastructure, or may even be a promising alternative to cytology 10 .
Methylation analysis can be performed on the same DNA isolate as used for HPV DNA testing, and has an objective read-out.
an internal control in a multiplex reaction using a single aliquot of DNA, thereby saving material, time and costs, and improving throughput and quality control 19 . A prototype version of a commercial, standardized multiplex qMSP test including CADM1 and MAL targets, has recently been developed (PreCursor-M assay, Self-Screen B.V., Amsterdam, The Netherlands).
In conclusion, combined cytology and methylation marker testing by the CADM1/MAL panel, is an attractive triage strategy for colposcopy of hrHPV-positive women with a high reassurance for cervical cancer and advanced CIN lesions.
